首頁 › 轉移性癌症 › 密蘇里 › Kansas City
Kansas City, MO 的 轉移性癌症 臨床試驗
15 項針對 轉移性癌症 的研究正在 Kansas City（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
招募中1 期
- St. Lukes Hospital of Kansas City, Kansas City
A Study of ASP3082 in Adults With Advanced Solid Tumors
招募中1 期
- University of Kansas Medical Center, Westwood · 距離 5 英里
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
招募中1 期
- University of Kansas Hospital-Westwood Cancer Center, Westwood · 距離 5 英里
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
招募中1/2 期
- University of Kansas Medical Center, Westwood · 距離 5 英里
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
招募中2/3 期
- Premier Imaging, Kansas City
- St. Joseph Medical Center, Kansas City
- MidAmerica Cancer Care - American Oncology Partners, Kansas City
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
招募中1 期
- The University of Kansas Medical Center, Westwood · 距離 5 英里
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
招募中3 期
- HCA Midwest Kansas City, MidAmerica Division, Inc., Kansas City
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
招募中3 期
- Saint Luke's Cancer Institute, Kansas City
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
招募中3 期
- The University of Kansas Cancer Center - Westwood, Westwood · 距離 5 英里
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
招募中1/2 期
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Hospital-Westwood Cancer Center, Westwood · 距離 5 英里
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
招募中3 期
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Cancer Center, Westwood · 距離 5 英里
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
招募中3 期
- Saint Luke's Cancer Institute, Kansas City
- The University of Kansas Cancer Center, Westwood · 距離 5 英里
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
招募中2/3 期
- MidAmerica Cancer Care, Kansas City
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
招募中3 期
- University of Kansas Cancer Center, Westwood · 距離 5 英里
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Kansas City
其他城市的 轉移性癌症 試驗
- Houston, TX104 項研究
- New York City, NY93 項研究
- Nashville, TN70 項研究
- Boston, MA63 項研究
- Los Angeles, CA57 項研究
- St. Louis, MO54 項研究
- Arlington, VA53 項研究
- Philadelphia, PA46 項研究
- Chicago, IL45 項研究
- San Antonio, TX44 項研究
- Washington, DC43 項研究
- Dallas, TX42 項研究
Kansas City 的其他研究
- 乳癌34 項研究
- 非小細胞肺癌31 項研究
- 心臟衰竭25 項研究
- 癌症（所有類型）21 項研究
- 肺癌19 項研究
- 大腸直腸癌16 項研究
- 急性髓系白血病15 項研究
- 前列腺癌14 項研究
- 卵巢癌11 項研究
- 肥胖症11 項研究
- 第二型糖尿病11 項研究
- 心血管疾病11 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。